SAN DIEGO, May 1 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. announced today that it has filed a shelf registration statement on Form S-3 with the U.S. Securities and Exchange Commission (SEC).
The shelf registration statement, when declared effective by the SEC, would give the Company the ability to offer and sell up to $100 million dollars worth of its common stock. After the shelf registration becomes effective, the common stock may be issued from time to time and through one or more methods of distribution described in the registration statement, subject to market conditions and the Company’s capital needs. The terms of any future offerings would be established at the time of the offering. Proceeds from any offering may be used for general corporate purposes, including financing its clinical development programs.
A registration statement relating to these securities has been filed with the SEC but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.
A copy of the prospectus included in the registration statement may be obtained at the SEC’s website at www.sec.gov/ or through the Investors section of the ADVENTRX Web site at www.adventrx.com. In addition, the Company would file a prospectus supplement with the SEC in connection with any offering under the shelf registration statement. The information on the Company’s Web site is not a part of the registration statement, the prospectus or any prospectus supplement which may be issued under the registration statement.
About ADVENTRX
ADVENTRX Pharmaceuticals is a biopharmaceutical research and development company focused on introducing treatments for cancer and infectious diseases that surpass the performance and safety of existing drugs, by addressing significant problems such as drug metabolism, toxicity, bioavailability and resistance. More information can be found on the Company’s Web site at www.adventrx.com.
Forward-Looking Statement
This press release contains forward-looking statements, within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, regarding ADVENTRX. Such statements are made based on management’s current expectations and beliefs. Actual results may vary from those currently anticipated based upon a number of factors, including uncertainties inherent in the drug development process, the timing and success of clinical trials, the validity of research results, and the receipt of necessary approvals from the FDA and other regulatory agencies. For a discussion of such risks and uncertainties, which could cause actual results to differ from those contained in the forward-looking statements regarding ADVENTRX, see the section titled “Risk Factors” in ADVENTRX’s last annual report on Form 10-K and its Quarterly Reports on Form 10-Q, as well as other reports that ADVENTRX files from time to time with the Securities and Exchange Commission. All forward-looking statements regarding ADVENTRX are qualified in their entirety by this cautionary statement. ADVENTRX undertakes no obligation to release publicly any revisions to forward-looking statements to reflect events or circumstances which occur after the date hereof.
ADVENTRX Pharmaceuticals, Inc.
CONTACT: Ioana Hone, Investor relations, or Andrea Lynn, both of ADVENTRXPharmaceuticals, Inc., +1-858-552-0866
Web site: http://www.adventrx.com//
Company News On-Call: http://www.prnewswire.com/comp/920134.html/
